Confronto
Goserelin vs. Triptorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
65807-02-5
57773-63-4
Peso molecolare
1269.43 g/mol
1311.45 g/mol
Emivita
4.2 h
3 h
Sequenza
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Meccanismo d'azione
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
4
4
Effetti registrati
3
3
Contraddizioni aperte
1
0
Eventi avversi documentati
2
3
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Goserelin and Triptorelin?
- Goserelin is classified as "Ricerca (altro)", while Triptorelin is classified as "Ricerca (altro)". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Triptorelin?
- The highest available evidence level is "RCT sull'uomo" for Goserelin and "RCT sull'uomo" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Triptorelin in Germany and the United States?
- Germania: Goserelin — Su prescrizione, Triptorelin — Su prescrizione. Stati Uniti: Goserelin — Su prescrizione, Triptorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.